Efficacy and safety of PT20, an iron-based phosphate binder, for the treatment of hyperphosphataemia: a randomized, double-blind, placebo-controlled, dose-ranging, Phase IIb study in patients with haemodialysis-dependent chronic kidney disease | Zendy

M Sampson | Zendy; Nuno Faria | Zendy; Jonathan J. Powell | Zendy

Open Access

Efficacy and safety of PT20, an iron-based phosphate binder, for the treatment of hyperphosphataemia: a randomized, double-blind, placebo-controlled, dose-ranging, Phase IIb study in patients with haemodialysis-dependent chronic kidney disease

Author(s) -

M Sampson,

Nuno Faria,

Jonathan J. Powell

Publication year - 2020

Publication title -

nephrology dialysis transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.654

H-Index - 168

eISSN - 1460-2385

pISSN - 0931-0509

DOI - 10.1093/ndt/gfaa116

Subject(s) - phosphate binder , dose ranging study , placebo , medicine , double blind , randomized controlled trial , phosphate , hemodialysis , hyperphosphatemia , clinical endpoint , phases of clinical research , sevelamer , clinical trial , urology , kidney disease , chemistry , pathology , alternative medicine , organic chemistry

Hyperphosphataemia is a common complication of chronic kidney disease (CKD). PT20 (ferric iron oxide adipate) is an investigational molecule engineered to offer enhanced phosphate-binding properties relative to other phosphate binders.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research